PharmaPoint: Meningococcal Vaccines - United Kingdom Drug Forecast and Market Analysis to 2022

United Kingdom’s Drug forecast foresees a spectacular growth during 2011-2022. The launch of Serotype B vaccine has brought the critical unmet need in the treatment of Meningococcal disease to a better aid. As the acute infection’s rapid onset and severity of symptoms’ diagnosis is highly difficult, vaccines play a vital role in fighting of the disease caused by the gram-negative bacterium Neisseria meningitidis The tetravalent conjugate vaccines such as Sanofi’s Menactra and Novartis’ Menveo, accounted for major sales and growth of Meningococcal vaccines will be driven by Serotype B vaccines until the launch of Serotype B vaccines.

Patient share for 3 MenC conjugate vaccines will shift due to changes made to the UK MenC schedule (DOH, 2013b). Menjugate and NeisVac-C are expected to be combination of prescription for patients after elimination of single primary dose of Meningitec.

Spanning over 129 pages, 37 tables and 4 figures, PharmaPoint: Meningococcal Vaccines - United Kingdom Drug Forecast and Market Analysis to 2022  report addresses important factors such as Overview of Meningococcal Vaccines, safety and efficacy profiles as well as a SWOT analysis of companies in United Kindom and Sales forecast for the top drugs in the UK from 2012-2022.